Document is current
Any future updates will be listed below
-
Authors
Wijaya, Lukas S.
Kunnen, Steven J.
Trairatphisan, Panuwat
Fisher, Ciarán P.
Crosby, Meredith E.
Schaefer, Kai
Bodié, Karen
Vaughan, Erin E.
Breidenbach, Laura
Reich, Thomas
Clausznitzer, Diana
Bonnet, Sylvestre
Zheng, Sipeng
Pont, Chantal
Stevens, James L.
Le Dévédec, Sylvia E.
van de Water, Bob
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030, 116030)
Partnership for the Assessment of Risks from Chemicals (10105714, 10105714)
- License Information
-
More Information
Article History
Received: 20 September 2024
Accepted: 12 February 2025
First Online: 21 February 2025
Declarations
:
: Both animal dosing studies were performed at AbbVie Deutschland GmbH & Co. KG (Knollstrasse, 67061 Ludwigshafen, Germany) in accordance with the German Federal Animal Welfare Act.
: M.E.C, currently employed at Regeneron Pharmaceuticals Inc, contributed to this article as an employee of Abbvie and the views expressed do not necessarily represent the views of Regeneron Pharmaceuticals Inc. P.T, currently employed at Sanofi, contributed to this article as an employee of Abbvie and the views expressed do not necessarily represent the views of Sanofi.
